Abiopharma

🔍 FRANCISCO PARTNERS IV, L.P. (Executive)

Company: GoodRx Holdings, Inc. (GDRX)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Sold 72,309 shares of Class A Common Stock at $3.462 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: false | shares_owned_after: 716,801.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 71,285 shares of Class A Common Stock at $3.462 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: false | shares_owned_after: 706,649.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 64,090 shares of Class A Common Stock at $3.4449 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 652,711.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Sold 63,183 shares of Class A Common Stock at $3.4449 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 643,466.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Sold 213,401 shares of Class A Common Stock at $3.5125 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 439,310.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 210,378 shares of Class A Common Stock at $3.5125 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 433,088.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 439,310 shares of Class A Common Stock at $3.5 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3
• Sold 433,088 shares of Class A Common Stock at $3.5 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/24/2026 at prices ranging from $3.425 to $3.5 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The reported amount has been adjusted by 721 shares to reflect the sale of such shares by Francisco Partners IV-A, L.P. on August 20, 2026, which were inadvertently reported on a Form 4 filed by the reporting persons on August 21, 2026, as being sold by Francisco Partners IV, L.P.
• F3: Francisco Partners GP IV, L.P. is the general partner of each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Francisco Partners GP IV Management Limited is the general partner of Francisco Partners GP IV, L.P. Francisco Partners Management, L.P. serves as the investment manager for each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Voting and disposition decisions at Francisco Partners Management, L.P. with respect to the shares of Class B common stock held by Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. are made by an investment committee. Each of Francisco Partners Management, L.P., Francisco Partners GP IV Management Limited, and Francisco Partners GP IV, L.P. may be deemed to share voting and dispositive power over the shares of Class B common stock held, but disclaims beneficial ownership.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/25/2026 at prices ranging from $3.415 to $3.48 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/26/2026 at prices ranging from $3.44 to $3.545 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.